PTX
Prescient Therapeutics Ltd
Director Trades
| Date | Director | Value |
|---|---|---|
| G. Shepherd | $26,133 | |
| M. Farris | $11,775 | |
| J. Campbell | $9,990 | |
| J. Campbell | $30,000 | |
| G. Shepherd | $20,000 | |
| M. Farris | $15,000 |
Company News
Prescient Therapeutics Moves Advanced PTX-100 Cutaneous T-Cell Lymphoma Therapy Closer to Commercialisation
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug to meet a significant market need, potentially converting years of work into billions of dollars. The company’s lead candidate PTX-100 is now in its all-important Phase 2 clinical trials. It is at this stage where data read-outs can provide […]
Prescient Therapeutics Confirms First US Site for PTX-100 Phase 2a Refractory Cutaneous T-Cell Lymphoma Trial
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a trial of PTX-100 for patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL). The Massey Comprehensive Cancer Centre at Virginia Commonwealth University – ranked as one of the top cancer research centres in the […]
Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the back of outstanding Phase 1b clinical trial data for lead candidate PTX-100 to treat cutaneous T-cell lymphoma (CTCL). Now in its Phase 2a trial, the advanced drug has delivered a 64% tumour halt or shrinkage in patients with […]
Prescient Therapeutics gains fast-track FDA designation for PTX-100 to treat T-cell lymphoma
Prescient Therapeutics (ASX: PTX) has received fast-track designation from the US Food and Drug Administration for lead candidate PTX-100 to treat adults with relapsed or refractory mycosis fungoides. The skin condition – a type of blood cancer – is the most common subtype of cutaneous T-cell lymphoma (CTCL). The FDA’s fast-track process aims to expedite […]
Prescient Therapeutics to present latest cancer treatment breakthroughs at world-leading conference
Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from its latest cancer treatment study at the world’s largest hematology event. Prescient’s abstract for results of its phase 1b study in T cell lymphomas has been accepted for poster presentation at the prestigious American Society of Hematology (ASH) […]
Prescient Therapeutics prepares for ‘pivotal’ year of PTX-100 development to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023 which it says has set the stage for a pivotal 12 months to come and beyond. Front and centre of the company’s strategy is commercialising its targeted cell therapies, primarily lead candidate PTX-100 to treat T-cell lymphomas (TCLs). […]
Prescient Therapeutics to present OmniCAR and CellPryme abstracts at international gene therapy conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual conference of the International Society of Cell & Gene Therapy (ISCT) in France later this month. Prescient researchers will showcase new preclinical data on the company’s next-generation immune receptor platform OmniCAR and its cell therapy enhancement platform CellPryme. […]
Prescient Therapeutics’ PTX-100 continues showing promising results in clinical T cell lymphoma trial
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced continuing positive results in the PTX-100 phase 1b expansion cohort for relapsed and resistant T cell lymphomas (TCL). The study, led by renowned haematologist Professor H Miles Prince at Melbourne’s Epworth Hospital, has demonstrated promising clinical activity and excellent safety. Since the last update in November […]
Prescient Therapeutics receives FDA orphan drug status for PTX-100 to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US Food and Drug Administration (FDA) for its lead candidate PTX-100 for the treatment of T-cell lymphomas (TCLs) including cutaneous TCL (CTCL). TCLs are a group of lymphomas that develop when white blood cells (lymphocytes) grow out of control. […]
Prescient Therapeutics to progress innovative pipeline of cancer treatments with capital raise
Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum in developing its pipeline of innovative cancer and cell therapies and move towards first-in-human clinical studies. Prescient has a broad pipeline of personalised cancer treatments, comprising two cell therapy platforms (OmniCAR and CellPryme-M) and targeted therapies spanning a range […]
Company Videos
PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies
Prescient Therapeutics furthers development of novel anti-cancer targeted therapies
Prescient Therapeutics tops-up cash reserves to progress innovative cancer therapies
Prescient Therapeutics advances innovative cancer therapies following successful FY 2021
